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1. Introduction
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the progressive
loss of dopaminergic mesencephalic neurons. The most used and successful therapy for this
condition is L-3, 4 dihydroxyphenylalanine (L-DOPA), a precursor in the synthesis of dopa‐
mine. However long-term treatment leads to disabling abnormal involuntary movements
known as L-DOPA-induced Dyskinesia (LID), which are uncontrolled and repetitive move‐
ment in the axis, arms, legs and oro-facial zone [1-2]. The LID is a serious limitation in the
usage of L-DOPA and it can be thought that solving the diskinesia by new therapeutic tar‐
gets could extend the time of treatment with L-DOPA in the parkinsonian patients with an
acceptable quality of life. To propose new alternatives is necessary to know the pathogenesis
and pathophysiology of this phenomenon.
According with the classical basal ganglia model [3], PD is the result of an imbalance in the
motor networks that stimulate and/or inhibit the initiation of movements. There are two
main pathways that have been studied in the basal ganglia. The direct pathway, which is
associated with D1-like dopamine receptors, and the indirect pathway that it has been relat‐
ed with D2-like dopamine receptors. The adequate balance between the direct (stimulatory)
and indirect (inhibitory) networks facilitates the execution of movements [4]. In PD the loss
of dopaminergic control leads to a hyperactivity of the inhibitory pathway, which produces
bradykinesia the main symptom of this disease [5]. The restoration of dopamine with L-
DOPA counteract the unbalance of the two pathways, nevertheless several cellular and mo‐
lecular changes caused by L-DOPA move the system toward the opposite side, producing a
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hyperactivity of the direct pathway and originating the dyskinesia phenomenon [5]. Many
changes in basal ganglia circuitry have been associated with dyskinesia [6]; one of the most
studied is the hyperactivity of direct pathway that produces an increased GABAergic neuro‐
transmission on striato-nigral neurons, which are controlled by dopamine D1 receptors, and
it seems to be the most relevant finding. The dopamine D3 receptors have been involved in
dyskinesia since was reported that L-DOPA treatment increases its expression in basal gan‐
glia [7], suggesting the use of ligands of these receptors as a target for dyskinesia, but the
neurobiological basis of these changes and the site of action is not well understood since
conflicting results in experimental assays have been reported [8-12]. The recent finding of
co-existence and interaction between D1 and D3 dopamine receptors in the direct pathway
[13-16] could contribute to solve this question.
The aim of this review is provide a global view of the pathophysiology of dyskinesia based
on the changes reported in animal models and parkinsonian patients that involve the direct
pathway and the dopamine D1 and D3 receptors, the understanding of this changes could
result in a potential novel therapeutic approaches to treat the dyskinesia.
2. Basal ganglia, the control of movement and Parkinson’s disease
Basal ganglia are organized in four segregated circuits: motor, oculo-motor, limbic and asso‐
ciative [17]. In PD the motor loop is altered in these structures. The basal ganglia circuit orig‐
inates in glutamatergic cortical neurons from motor and premotor areas that project to
caudate (C) and putamen (P), the striatum in rats (Str). The main phenotype of striatum is
the GABAergic medium-size spiny neurons (MSNs), which projects to the direct and indi‐
rect pathways. The substance P/Dynorphyn positive MNSs GABAergic neurons project to
substantia nigra pars reticulata (SNr) and/or to the internal segment of globus pallidus
(GPi), the entopeduncular nucleus (EPn) in rats. SNr and GPi is the output nucleus of the
motor loop to the thalamic glutamatergic nucleus, which in turn stimulates the motor cortex;
this network is called the direct pathway. While the striatal enkephaline positive MNSs GA‐
BAergic neurons project to the external segment of the globus pallidus (GPe), pallidal GA‐
BAergic neurons which in turn project their axons to the glutamatergic neurons of the
Subthalamic nucleus (Sth) and this neurons project to the output nuclei forming the indirect
pathway [17]. (See Fig. 1).
Neurons of the thalamic relay nucleus are subject to a tonic inhibitory control from GABAer‐
gic GPi/SNr neurons, the removal of this control leads to the activation of thalamus that in
consequence activates the motor cortex facilitating the movement. The activity of GPi/SNr
neurons is maintained by a tonic stimulatory action of the Sth controlled reciprocally by the
GPe. Stimulation of the MNSs GABAergic striatal neurons by the cortex in the direct path‐
way produces inhibition of the output nucleus through the release of GABA. The remotion
in the inhibition of the thalamus toward to the cortex turns in the initiation of the move‐
ment, thus the activation of the direct pathway allows the movement. In contrast the activa‐
tion of MNSs GABAergic neurons from the indirect pathway inhibits GPe neurons, which
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removes the tonic inhibitory action on Sth, the increased activity of the glutamatergic neu‐
rons stimulates the output nuclei, producing inhibition of thalamus and in consequence in‐
hibit the motor cortex, which means that the activation of the indirect pathway inhibits the
movements.
Simultaneous activation of the direct and indirect pathway will produce an antagonistic ac‐
tion on movement. The adequate balance between direct and indirect pathway is main‐
tained by dopamine. The Substantia nigra pars compacta (SNc) is the source of dopamine in
the basal ganglia since SNc neurons project to all the basal ganglia nuclei (Fig.1A) in normal
conditions [18].
Figure 1. The basal ganglia motor circuits in normal (A), parkinsonism (B) and L-DOPA-induced dyskinesia (C). GPe,
external globus pallidus; Sth, subthalamic nucleus; GPi, internal globus pallidus; SNr, substantia nigra pars reticulata;
SNc, substantia nigra pars compacta, D1, dopamine D1 receptor and D2, dopamine D2 receptor.
Two families of receptors mediate the action of dopamine through the basal ganglia, D1-like
(D1 and D5 subtypes) and D2-like (D2short, D2long D3 and D4 subtypes). D1-like receptors are
expressed predominantly in substance P/Dynorphyn positive MNSs GABAergic neurons
and their activation increases the firing rate at soma and also the GABA release in the termi‐
nals [19-22]. It have been reported that some population of striato-nigral neurons also ex‐
presses D3 receptors [14, 23]. While the dopamine D2-like receptors are associated to striatal
enkephalin positive MNSs GABAergic neurons and their activation decreases the firing at
soma and the GABA release at the terminals [20, 24-26]. Some population of striato-palidal
neurons also expresses D5 receptors [23]. Dopamine via D1-like receptors potentiates the
stimulation of the direct pathway, while via D2-like receptors decreases indirect pathway
activity, synergizing the activity of both pathways and facilitating movement [17]. Other as‐
sociation of dopamine receptors subtypes with neuronal elements of these circuits occurs
[27-32], however the role of their function in the integral circuitry is not well understood.
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The progressive loss of dopaminergic neurons of the SNc causes the neurodegenerative dis‐
order called Parkinson’s disease. The loss of dopamine has serious consequences in the bal‐
ance of direct and indirect pathways, in fact a hyperactivity of the indirect pathway with a
decrease in the activity of the direct pathway coexists and that explains the hypomotility or
bradykinesia observed in patients and in animal models of PD (Fig. 1B) [17].
3. Pathophysiology of L-DOPA-induced dyskinesia (LID)
Dopamine replacement therapy with L-DOPA restores the lack of the neurotransmitter in
the basal ganglia [33]. It has been shown that L-DOPA (a precursor in dopamine synthesis,
Fig. 2) is transformed to dopamine in the central nervous system by decarboxylation via cen‐
tral aromatic acid decarboxilase (DCAA) [34]; also it has been proposed that remaining dop‐
aminergic neurons (Fig. 2) and/or serotoninergic neurons are host candidates for
transformation of L-DOPA [35], mediating an ectopic and false transmitter release [36] in
fact any cell that express DCAA can eventually transform L-DOPA into dopamine. The dop‐
amine synthesized from L-DOPA activates D1-like and D2-like family of receptors. Howev‐
er it has been also suggested the existence of DOPAergic receptors [37], since direct effects of
L-DOPA on dopamine receptors have been reported [19, 38 -39] but also effects are mediat‐
ed by either L-DOPA or their metabolites [39, 40-41] that could participate in their therapeu‐
tic or side effects including dyskinesia [42-43]. Probably the effectiveness of L-DOPA over
dopamine receptor agonist is due to a variety of actions in the central nervous system [44].
Figure 2. Synthesis of dopamine from L-DOPA in the dopaminergic nerve terminals. DCAA, aromatic acid decarboxy‐
lase; DAT, dopamine transporter, TH, Tyrosine Hydroxylase; D1, D1-like dopamine receptor; D2, D2-like dopamine re‐
ceptor.
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During L-DOPA treatment the activation of dopamine receptors restores the movement in
PD patients and the locomotor activity in experimental animal models. L-DOPA treatment
produces a priming effect where the brain is sensitized to L-DOPA after chronic administra‐
tion and finally produces dyskinesia as main side effect [45] with a prevalence of 30-45% in
patients [46]. However early age of Parkinsonism onset and severity of disease have been
classified as risk factors in the development of LID [47] and more recently the nigral-associ‐
ated pathology has been related with early onset of LID [48]. It has been shown that phar‐
macokinetic properties of L-DOPA are also related with the onset of dyskinesia with
phenomenological differences in the altered movements. When the higher plasma levels of
L-DOPA are reached the maximum antiparkinsonic effect can be achieved. In contrast dys‐
kinesia occurs at intermedium L-DOPA plasma levels either when bioavailability is increas‐
ing or decreasing due to metabolism of L-DOPA, interesting when the lower L-DOPA
plasma levels are reached generalized dystonic postures occurs [49].
The dyskinesia also has been observed in experimental models of PD under chronic L-
DOPA treatment [50], the effect is dose and species dependent, since different population
with high and low dyskinesia score have been reported [51-52].
The mechanism of the genesis of dyskinesia is essentially unknown. Initial studies suggest‐
ed that L-DOPA or metabolites could be responsible of the side effects, however the inhibi‐
tion of L-DOPA decarboxylation, does not correlate with LID scores [53]. Plenty evidence
has been published recently showing that several compensatory effects occur after dopa‐
mine denervation and LID.
The changes in nuclear function of striato-nigral and striato-pallidal neurons have been re‐
lated with denervation, most of them are associated with proteins involved in the dopamine
receptors signaling and in the regulation of glutamatergic transmission by dopamine [54], it
can be though that L-DOPA therapy should restore these parameters. However that is not
the case since the major alterations related to LID occur on these cellular systems [52, 55-60].
It has been reported alteration in gene expression during L-DOPA therapy particularly on
transcription factors. Early gene expression which are markers of neural activity has been
studied and increased expression of the transcription factor ΔFosB has been associated with
L-DOPA induced dyskinesia in rats and related with sensitization process [61-64], while ac‐
cumulated ΔJunD has been shown drop the severity of LID in monkeys without reduction
of antiparkinsonian effects [63]. Also zif-268 has been related with a persistent stimulation of
D1 receptors by L-DOPA and has been proposed like a potential marker for the onset of the
dyskinetic phenomena [65]. On the other hand histone activation mediated by D1 receptors
it has also been related with dyskinesia [66-67] suggesting that changes in gene transcription
factors are altered, then is plausible suggest that many alterations in signaling molecules ac‐
tivated by dopaminergic receptors could contribute to the leading of motor disabilities. The
resulting changes of the altered activity culminates with expression of proteins related with
the activity of D1-associated neurons like the increased expression of prodynorhin, glutamic
acid decarboxylase, adenylyl cyclase, PKA, DARPP-32 and CDk5 [52, 54-60].
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Nevertheless LID can be also pathophysiologically explained by a change in the balance of
the direct/indirect pathway. In this condition an increase in the activity of the direct path‐
way that facilitates movements can explain the phenomena (Fig. 1C) [5]; since the direct
pathway stimulates movement, dyskinesia can be considered a pathologic condition with
over-activation of this pathway generated by pulsatile activity of striato-nigral neurons. In
fact experimental data supports this idea; a higher release of GABA in SNr/EP has been
shown in experimental models of LID [52,68], which in turns facilitates the inhibition of the
output neurons and removes the inhibition of premotor nuclei leading activation of the
movement.
The role of the indirect pathway and dopamine D2-like receptors is less understood and ex‐
plored. An over-activity of the GPe is associated with LID [55], and dopamine D2 receptors
[69- 71]; however pallidotomy does not modify significantly LID in hemiparkinsonian mon‐
keys [72]. Some D2-like agonist has beneficial effect on L-DOPA induced dyskinesia [73],
but the genetic inactivation of dopamine D2 receptor expression in striatum does not modify
the development of LID [66]. On the other hand D2 dopamine receptor agonist treatment in
PD models produce lower LID compared with D1 receptor agonist treatment suggesting a
predominantly role of dopamine D1 receptors [65,74]. Interesting recent reports have shown
that L-DOPA restores spine density in D2-expressing striatal neurons of LID mice [75], sug‐
gesting an undefined role of striato-pallidal in the dyskinetic phenomenon. On the other
hand adenosine A2A receptors are selectively expressed in the indirect pathway and an in‐
creased expression of these receptors was found in patients with LID [76], the A2A/D2 recep‐
tor heterodimer interaction has been suggested is modified during LID in the indirect
pathway [77]. All this data suggested a role of the indirect pathway in LID development;
however further studies are needed to clarify the role of D2 receptor and the indirect path‐
way in the dyskinesia phenomenon.
Other non-dopaminergic alterations have been involved in LID, which contributes to this
phenomenon. The idea of a role of the glutamatergic system in LID comes from the use of
amantadine in Parkinson’s disease and as an adjuvant in the management of LID [78], in fact
amantadine increases extracellular dopamine from L-DOPA in parkinsonian rats [79]. Dopa‐
minergic denervation decreases the expression and phosphorilation of NR1 subunit of the
NMDA receptor without change in NR2 subunit. L-DOPA restores the expression of the
subunit but also increases the phosphorilation level of the NR2A subunit with a consecutive
high activity of the NMDA channel [80-81]. It has been shown also that D1-like receptors in‐
crease the phosphorylation of the channel subunits through the PKA signaling pathway
[82-83]. Furthermore D1 receptor promotes the expression of NMDA in membrane [80] and
can interact at the level of protein [84], in consequence if a generalized hypersensitivity of
D1-like receptor activity occurs, the NMDA receptor activity will also be potentiated [80,
85]. Dopamine modulates long-term potentiation (LTP) of the glutamatergic system, in con‐
sequence in dyskinesia, L-DOPA could contribute to the prolongation of this effects [78, 86].
It has been shown in dyskinetic rats an increased levels of PSD-95 and SAP97 proteins of the
postsynaptic density, those proteins are involved in the interaction of NMDA and AMPA
receptors in the membrane, but their participation in the phenomenon has not been com‐
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pletely determined [87-89]. The consequence in all these alterations of the glutamatergic sys‐
tem is a higher excitatory transmission to the direct pathway. An interesting review on the
role of D1/NMDA interaction and LID is found in Fiorentini et al., 2008 [90]. Changes in syn‐
aptic plasticity induced by L-DOPA also occur in the output nuclei [91].
The role of the serotoninergic system on LID comes from the hypothesis of conversion of L-
DOPA to dopamine in serotoninergic neurons and nerve terminals within the basal ganglia
[92, 93]. It has been suggested a false-transmitter release of dopamine from this neurons [36,
94], in consequence a higher dopaminergic activity would be the responsible of LID. Ac‐
cording with this hypothesis the role of serotonin system in LID is related with effects on
dopamine formed in the terminals. Some studies indicates that increasing serotonin levels
suppress LID, the effect seem to be mediated by 5-HT1A receptors [95], since these receptors
are also located at cortico-striatal glutamatergic terminals is plausible that blockade of D1
receptor activity explains the therapeutically effect [96]. Moreover blockade of serotonin
transporter also attenuates LID suggesting that a reduce turnover [95] and activation of se‐
rotonin receptors is involved in its beneficial effect.
Dopamine denervation and L-DOPA treatment increases mRNA codifying opioid precur‐
sors pro-enkephaline A and B, which correlates with the development of dyskinesia [55, 97].
This effect has been observed in striato-nigral neurons [98] and has been postulated partici‐
pate in LID due to an enhanced coupling of opioid receptors to G protein [99]. However the
blockade of these receptors in dyskinetic rats does not prevent symptoms and in fact there is
an increase in the dyskinesia score [100, 101]. It seems that the over-expression is just conse‐
quence of denervation, recent studies have been shown that modification of δ-opiod recep‐
tor modify dyskinesia in hemiparkinsonian rats [102], but the role of opioids in LID remains
unclear and needs further study. Finally the role of noradrenergic system in LID is poorly
studied but it has been suggested that an increased norepinephrine transmission in Str could
be related with dyskinesia since the blockade of norepinephrine receptors reverts LID [103].
Since the direct pathway of the basal ganglia and D1 receptors activity is associated with
dyskinesia, the research has been focusing on changes in these neurons, their activity, neu‐
rochemical tracers and their receptors particularly dopamine D1 and D3 receptors, in order
to propose alternatives to the therapeutic management of the Parkinson patients.
4. The dopamine D1-like receptors signaling in the direct pathway
D1-like family of dopamine receptors includes D1 and D5 subtypes. D1 has 466 amino acids
and D5 has 477 with a homology of 80% located mainly in the transmembrane domains
[104]. D1 and D5 receptors have a differential distribution in the central nervous system;
moreover there is a controversy of their signaling pathway. Initially was proposed that both
receptors stimulate adenylyl cyclase; however some dopamine effects on PLC activity seem
to be mediated by the D5 type [105].
Dopamine D1 receptors are members of the G protein coupled receptors family (GPCRs)
stimulates adenylyl cyclase trough Gαolf or Gαs proteins [106]. In the D1-like receptors asso‐
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ciated to the striato-nigral neurons, the subunit Gαolf interacts with the catalytic domain of
adenylyl cyclase V [107], increasing the activity and therefore cAMP formation [108]. It have
been reported Gαolf is expressed in the direct pathway and the level of expression can
change after dopamine denervation [52].
The cAMP formed by D1 receptor activation stimulates PKA, and recent studies suggested
the activation of the GEF (nucleotide interchange factor) EPAC and the consequence activa‐
tion of Rap1 a low weight G protein that activates MAPK [109]. The activation of PKA phos‐
phorylates several substrates that include: Na+, voltage depending K+ and GIRKs channels,
producing inhibition; whereas Ca2+ L, N, P, Q, NMDA, AMPA and GABAA channels are
stimulated by the phosphorylation. PKA also phosphorylates DARPP-32 at threonine 34,
DARPP-32 phosphorylated inhibits protein phosphate 1 (PP1). Phosphorilation of NMDA
channels by D1 receptor signaling through DARPP-32, synergize their stimulatory action,
whereas by the same pathway attenuates GABAA inhibitory currents. PP1 has several sub‐
strates such as Ca2+ L, N, P and AMPA channels (for references see Udieh, 2010 [105]).
D1 receptors also induce activation of anti-apoptotic signals. PKA phosphorylates Akt (also
known like PKB), which phosphorylates CREB that translocate to the nucleus inducing gene
expression related with cellular survival. D1 receptors interact with other receptors, ionic
channels and cytoskeleton proteins. Protein-protein interaction between NMDA at the level
of NR1 subunit produces signaling via PI3K, interaction with NR2 subunit decreases
NMDA current [105]. D1 receptors form heterodimers with adenosine A1 receptors produc‐
ing decrease in GABA release [110], while D5 receptor interacts with GABAA channels de‐
creasing Cl- current [111]. Neurofilament M, COP gamma and DIRP78 are cytoskeleton
proteins related with expression, sensitization, and transport of D1 receptors [105].
D1 receptor interactions with other dopamine receptors have been described. Dimmers be‐
tween D1-D2 receptors induce an increased intracellular Ca2+ probably mediated by the Gαq
→PLC pathway [112]. It has also been reported the interaction of dopamine D1/D3 receptors,
here we will discuss latter the role of this dimmer in PD and LID.
The adenylyl-cyclase→PKA stimulated by D1-like receptors induces GABA release in the Str
and SNr [19, 22, 113] and increases the firing rate MNSs [21], mechanism that has been relat‐
ed with the facilitation of movement in the direct pathway. Dopamine D1 receptor effects on
firing rate and GABA release are mediated by DARPP-32 and PP1 [21, 83, 113, 114]. The ef‐
fects on firing rate and release have been associated to modulation of L-type and P/Q calci‐
um channels [21, 113-116].
5. Mechanisms of D1 dopamine receptors sensitization in PD and LID:
Changes in signal transduction pathways
As we discuss before the loss of dopamine innervation induces molecular and signal trans‐
duction changes in the neurons of the basal ganglia attributed to a compensatory response.
Most of the experimental studies have been assessed using toxins to induce experimental
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models of PD like 6-hydroxydopamine (6-OHDA) for rats or 1-metyl-4-phenyl-1,2,3,6 tetra‐
hydropyridine (MPTP) for mice or non-human primates, because their ability to induce the
degeneration of dopaminergic neurons [117-118]. The changes after dopamine denervation
have been studied in particular on striato-nigral (direct pathway) and pallido-nigral (indi‐
rect pathway) neurons and plenty evidence shows that cellular and functional changes oc‐
curs, this phenomenon is called supersensitivity to dopamine denervation [119, 120]. The
supersensitivity has been shown in expression levels of mRNA for enkephalins, substance P
and dynorphins [121] but also up-regulation of more than 30 genes including zif 268, c-fos,
c-jun and MAPK-1, most of them related with neuronal activity [54, 122]. Interesting several
of those genes and changed proteins convey to D1 dopamine receptors and their signal
transduction pathways [54].
Perhaps one of the most studied effects of denervation is the altered expression of dopamine
receptors in the basal ganglia [20]. D2-like dopamine receptors increase in number, sensibili‐
ty and consistently with that the mRNA in the striato-palidal neurons[20], which explain the
hypomotolity. In contrast despite some contradictory results [56, 123], there is evidence that
not only the mRNA of D1-like dopamine receptors decreases in the striatal neurons [20] but
also the expression [124-125], with no changes in the affinity studied by radioligand binding
techniques in SNr [125]. Proteasome altered activity observed in L-DOPA treatment produ‐
ces an altered D1-like receptor abnormal trafficking that might be responsible for this
changes [126]. Contrary to the decrease of D1-like dopamine receptors an increased re‐
sponse to their activation is observed in the striatum [120, 122, 127], and also a substantial
increase in GABA release in the striato-nigral terminals [68, 125]. However despite the su‐
persensitivity phenomenon the lack of endogenous dopamine in PD to activate the receptors
explains the poor activation of basal ganglia pathways and therefore the hypomotility.
The activation of dopamine receptors would be the target in order to restore the balance in
the circuit of the basal ganglia. The gold-standard therapy in PD is L-DOPA, because is con‐
verted to DA, or even can activate dopamine receptors directly increasing firing rate in stria‐
tal neurons and inducing GABA release in SNr. In addition the activation of D1 receptors
leads an increase of GABA release in striato-nigral terminals promoting the activation of the
direct pathway related with the movement, which is the main purpose of the pharmacologi‐
cal approach to treat PD.
It can be thought that replacement of DA with L-DOPA should restore the number, sensitiv‐
ity and response of the activation of dopamine receptors observed in experimental condi‐
tions. Nevertheless that is not the case, chronic L-DOPA treatment only produces a partial
recovery of D1-like dopamine receptors [125], whereas increases even more the biological
response to their activation, producing a very high level of GABA release in the striato-nig‐
ral terminals than occurred only with dopamine denervation in hemiparkinsonian rats [125,
128-129]. An analysis of D1 receptor expression in striatum in L-DOPA treated rats indicates
that D1-like receptors activity does not go back to healthy conditions in LID [126]. During L-
DOPA treatment the expression of early genes like c-fos, c-jun and zif 268 is increased more
than observed in dopaminergic denervation [55]. Furthermore the effect was mimetized
[122] and synergized by D1 dopamine receptor agonists [130]. This suggested that the DA
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converted by L-DOPA treatment, activates D1 dopamine receptors producing high gene ex‐
pression and translation, causing an overstimulation of the direct pathway [119]. The high
activity of D1 dopamine receptors is also supported by the high expression of substance P
and dynorphin both markers of direct pathway neurons [55].
The abnormal activation of the direct pathway with increased GABA release in SNr (related
with the activation of the movement) could be occurring during LID as we mention before.
The changes in GABA transmission is supported by studies in which has been shown al‐
tered metabolic activity measured by 2-deoxyglucose during LID in striato-nigral terminals
[131] but also the increased expression of the enzymes responsible of synthesize GABA
[132]. The mechanism underlying the increased GABA release in the striato-nigral neurons
during LID has been studied by several groups of investigation [125, 128, 132-133] and some
hypothesis has been proposed.
First was postulated that the increased GAD65 and GAD67 expression observed in denerva‐
tion and L-DOPA treatment, induces an enhanced synthesis of GABA, which is available for
the release [132, 134]. However the fact that GABA contents in SNr is not altered by dener‐
vation [135] indicates that the synthesis of GABA is not a simple cause-effect relationship.
Then, studies of D1 dopamine receptors signaling in the striato-nigral terminals turned to be
the most studied and strong hypothesis. Since the level of expression of D1 dopamine recep‐
tors was contradictory and the down-regulation does not explain the hyperactivity of direct
pathway, their signal transduction pathways had been dissected. Cai and coworkers (2002)
[123] showed an increased coupling between D1 dopamine receptors and Gαolf proteins in
hemiparkinsonian rats, but the level of protein expression of Gαolf remained unchanged. In
contrast studies in postmortem patients with PD showed increased expression of Gαolf pro‐
teins [136] and the effect was also observed in hemiparkinsonian rats, interesting the effect
was reverted by chronic but not acute L-DOPA treatment [134], which was also demonstrat‐
ed in either mild or severe dyskinetic rats after chronic L-DOPA treatment [52]. Recent stud‐
ies have shown a persistent increase in Gαolf expression in dyskinetic mice [59] however the
reason for this discrepancy is unknown and requires more study.
In next steps downstream the activation of D1 receptors induces the activity of adenylyl cy‐
clase isoform V by coupling of Gαolf protein, which in turn induces the production of a sec‐
ond messenger cAMP in striato-nigral neurons and PKA activation, supersensitivity of D1
receptors could be in these proteins. Since cAMP modulates firing rate and GABA release in
striatum and SNr [113-114] and stimulates the protein kinase activated by cAMP (PKA)
which in turn can produce several effects that are related with GABA release, a higher ex‐
pression/or activity of adenylyl cyclase, PKA and DARPP-32 signaling was related with LID
[54]. Consequent with the activation of D1 receptors Ras-mTOR-ERK induced altered
mRNA translation was found in the nucleus striatum [57-58, 67, 120, 137]. However other
studies have been suggested that ERK hypersensitivity is not related with cAMP/PKA sig‐
naling and this is a condition is needed for the development of LID, whereas hypersensitivi‐
ty of cAMP/PKA has a permissive role [59]. Recent studies suggested that Shp-2
phosphatase is the link between D1 receptor activation and ERK, and that is persistent acti‐
vated in LID [60]. Probably ERK supersentivity is related with control of the expression of
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proteins related with cAMP/PKA pathway supersensitivity. The activation of cAMP/PKA is
the mechanism that conduces to the increased GABA release in the striato-nigral terminals
of the direct pathway of basal ganglia since GABA release is highly sensitive to cAMP (Fig.
3) [114, 125] and the increased activity through the direct pathway is a necessary condition
to produce the involuntary movements.
Rangel-Barajas and coworkers (2011) [52] have shown that a persistent increase in activity
and expression of adenylyl cyclase V/VI occurs in LID animals without changes in activity
of PKA of striato-nigral terminals. This change on the adenylyl cyclase V/VI is correlated
with an increased GABA release in SNr in severe dyskinetic rats and did not happened in
mild dyskinesia. It was also suggested an increased phosphorylation of DARPP-32 in Thr34
found in denervation and LID, this change cannot been associated exclusively with higher
GABA release since not all GABA released in striatum by D1 receptor stimulation is related
with DARPP-32, inferred from DARPP-32 know-out mice studies [138] and it’s likely that
the increased activity of adenylyl cyclase V could mediate the phosphorylation and there‐
fore activation of DARPP-32 via PKA [139]. Thus a higher expression/activity of adenylyl cy‐
clase seems to have a central role in the LID. Probably several beneficial effects that helps in
experimental therapies to control LID can be related with antagonistic actions on adenylyl
cyclase for example, 5HT1A receptor activation, which modulates negatively AC by Gαi pro‐
teins reducing LID [96, 140], CB1 receptor also coupled to Gαi proteins decreased LID and
PKA activation [141] and finally mGlu4 receptors modify also LID [142]. According with a
recent study showed by single exon sequencing, that the only gene codifying for adenylyl
cyclase V was mutated in a familiar form of dyskinesia [143]. Further in vivo studies are
needed to targeting adenylyl cyclase V in LID, to asses if the therapeutic is plausible, since
adenylyl cyclase V has a wide distribution and also plays an important role in cardiac func‐
tion [144], anxiety modulated by D1 dopamine receptors [145] and depression [146]. This da‐
ta suggested that the indirect modulation of the activity of adenylyl cyclase could be
effective in LID.
In summary LID could represent an exaggerated supersitivity of D1 receptor response to the
denervation induced by L-DOPA treatment leading to a pulsatile and high GABA release on
striato-nigral terminals through the sensitization of adenylyl cyclase activity.
6. Role of D3 dopamine receptors in Parkinson's disease
The D3 dopamine receptors are expressed mostly in limbic system, islands of Calleja, olfacto‐
ry bulb, and the pituitary intermediate lobe, with a low but significant expression in basal
ganglia structures [147]. The amino acid sequence homology for the helical transmembrane
spanning (TMS) segments of the D2 and D3 dopamine receptor subtypes was found to be
75-80%. Since the TMS regions are involved in the construction of the orthosteric-binding
site, the pharmacologic profiles of D2 and D3 receptors are very similar [148-150]. Probably
that is the reason why in PD the role of D3 dopamine receptors were poorly studied. The
pharmacological approach to treat PD besides L-DOPA was because D2-like dopamine ago‐
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nist showed effectiveness to treat bradykinesia [151]. In the past two decades with advanced
pharmacological and molecular tools, the role of D3 dopamine receptors became a potential
field of study in PD and LID animal models.
With very good agreement is known that during denervation, the D2-like dopamine recep‐
tors are up-regulated in pallido-nigral neurons of the basal ganglia [20], then it was unclear
whether or not the D3 dopamine receptors subtype was participating in the supersentitivity
by dopamine denervation, however their low expression in striatum made focus the atten‐
tion in D2 dopamine receptors [152]. It was pointed out that in the basal ganglia, the segre‐
gation of the expression of D1-like and D2-like dopamine receptors in the direct and indirect
pathways respectively was not precisely accurate, but a relative low abundance of D3 recep‐
tors were expressed also in the direct pathway [23]. Probably disease conditions enhance
their expression, according with that; recently it has been shown that D3 dopamine receptors
are up-regulated in caudo-putamen and SNc in Lewy Body disease and Parkinson disease
Dementia [153].
Bordet and coworkers (1997)[7] showed that mRNA codifying to D3 dopamine receptors re‐
mains unchanged during dopamine denervation, but the L-DOPA treatment induces a re‐
markable increase in dynorphin positive striatal neurons, which project to the SNr where D3
dopamine receptors normally has moderate expression. Interesting the binding for D3 dopa‐
mine receptors was decreased in hemiparkinsonian rats [148,154] but up-regulated when an‐
imals were treated with L-DOPA [7]. Since then, the ectopic over-expression of D3 dopamine
receptors has been related with L-DOPA induced behavioral sensitization in hemiparkinso‐
nian rats [119], and several studies support the idea that D3 dopamine receptors can attenu‐
ate the LID by normalizing their function [8, 11, 120]. However the location of D3 receptor
sensitized by L-Dopa treatment is not clear. On the other hand D3 dopamine receptors inter‐
act with proteins and/or form heterodimers with other receptors that can change signal
pathways and responses, e.g. D2/D3, D1/D3 heterodimers [14-16]. Recently it has been shown
that the up-regulation of D2 dopamine receptors in denervated striatum is probably mediat‐
ed by D3 receptors through Ca2+ channels [155]. All these finding together shown that sever‐
al changes in D3 receptor expression and function can be related with Parkinson Disease and
L-DOPA treatment.
7. D1/D3 dopamine receptors interaction in LID like a novel therapeutic
target
D3 receptors are members of the D2-like receptors are coupled to Gαi proteins [106]. It has
been shown classical Gαi responses mediated by these receptors: inhibition of adenylyl cy‐
clase, blockade of Ca2+ channels, open of K+ channels etc [106]. However interaction with D1
receptors produces an antagonistic and synergistic response [14, 156]; that depends of the
nuclei studied. In the antagonist interactions, D3 receptors prevent D1 receptor stimulatory
effects by the inhibition of adenylyl cyclase stimulated by D1 receptor, an interaction ex‐
plained by cross-talk inhibition the AC activity. In the synergistic interaction D3 receptors
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potentiates D1 effects, and this interaction seems to be more complex and explained in terms
of heterodimerization, where D3 receptor induces an increased sensitivity of D1 receptor for
dopamine, potentiating cAMP formation and stabilizing them in the membrane (Fig. 3)
[15-16]. This synergistic interaction occurs at the striato-nigral pathway and it’s regulated by
CAMKIIα during neural activity [13-14].
D3 receptors have been associated with different elements of the basal ganglia. The mRNA
codifying for D3 receptors have been shown in dopaminergic neurons [147], subthalamo-
nigral neurons [30] and striato-nigral neurons [23]. In dopaminergic neurons D3 receptors
controls the firing rate and dopamine release [157] and has neurotrophic effects [158]; proba‐
bly the decreased expression in D3 receptors observed in dopaminergic denervation [148,
154] occurs by the degeneration of the dopaminergic neurons. Several studies have pointed
out the importance of these receptors in nigral neurogenesis [158], neuro-protection and re‐
pair in PD [160] and other cognitive conditions related to PD [153].
Figure 3. Synergistic and antagonistic interaction between D1 and D3 dopamine receptors in the striato-nigral neu‐
rons. Glu, glutamate; DA, dopamine; GPe, external globus pallidus; Sth, subthalamic nucleus, SNr, substantia nigra
pars reticulata, GPi, internal globus pallidus; ACV, adenylyl cyclase V; PKA, protein kinase activated by cAMP.
In subthalamo-nigral neurons D3 receptors are probably controlling the firing rate and gluta‐
mate release that have been attributed to members of the D2-like receptor family [31-32].
Since during denervation subthalamic neurons shown high activity rates and contribute to
hypomotility, the D2-like agonist used in the control of Parkinson disease like pramipexole
or ropirinole are able to decrease neuronal firing or glutamate release leading a clinical im‐
prove of symptoms. Interesting these D3-preferring agonists decrease the dyskinesia.
As we mention D3 receptors interact with D1 receptors at striato-nigral neurons. The syner‐
gistic interaction has been shown in striatum [15-16] and substantia nigra on nerve terminals
[14]. In the interaction D3 receptors increases D1 receptor affinity for dopamine, increasing
cAMP formation and GABA release in striato-nigral terminals, this effect is very important
since the higher release of GABA seems to mediate LID. Co-precipitation in native tissue
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and studies using transferred energy like FRET and BRET in heterologous expression sys‐
tem indicate that the heterodimerization is the cause for the observed effects [13-16].
The D1/D3 dopamine receptors interaction is important in dopaminergic denervation and L-
DOPA treatment? The expression of D3 receptors in the striato-nigral and subthalamo-nigral
neurons leads the speculation that D3 receptors are involved in the motor control by poten‐
tiation of GABA release stimulated by D1 receptors and inhibition of glutamate release lead‐
ing to a decreased activity of the output neurons and increased activation of motor cortex.
These effects are expected occur by the administration of L-DOPA and explain their power‐
ful therapeutic effect; however the role of D3 receptors in subthalamo nigral and D1/D3 inter‐
action at striato-nigral neurons during denervation and L-DOPA treatment is unknown.
However behavioral experiments suggested that D3 dopamine receptor agonists potentiate
the D1 receptor-induced rotation in hemiparkinsonian rats only after L-DOPA treatment
[161] suggesting that the D1/D3 interaction persist.
Chronic L-DOPA therapy sensitizes D3 receptor expression, which has been related with
LID development and the therapeutic management was experimentally evaluated. Two cur‐
rent opinions are in literature, one proposed that the normalizing D3 function decreases LID
with partial agonists [8, 12], another one propose that antagonist also are able to do that
[10-11] while other suggested that antagonist does not modify LID [9].
The mechanisms through D3 dopamine receptors selective compounds can help to LID is
still unclear, but recent studies have suggested that it could be due to a modulation of D1
dopamine receptors or direct actions on D3 receptors. Albarran and coworkers [162] report‐
ed that activation of D3 receptors in hemiparkinsonian dyskinetic rats prevents the D1 dopa‐
mine receptor stimulation of GABA release at striato-nigral terminals and the effect is
mediated by an antagonist interaction between the receptors explained by a cross-talk as
previously described [156]. This change in the D1/D3 relationship observed in dyskinesia
with respect normal conditions could explain why D3 receptor agonist prevents dyskinesia
in L-DOPA treatment models, antagonizing adenylyl cyclase stimulated by D1 receptors
and in consequence GABA release. This observation also suggested that the maintenance of
the dyskinesia is due to the sensitization of the D1 receptor signaling pathway in the direct
pathway that has been related with the LIDs [52]. If the heterodimeric interaction between
D1 and D3 receptor is modified by L-DOPA remains unclear and more studies are needed to
clarify it. The effect of antagonist in LID need to be also clarified since current basal ganglia
models does not predict the effect observed, also the wide expression of D3 receptors in oth‐
er brain areas can contribute to the observed effect. However all the studies suggest that the
use of D3 receptors ligands on LID is promising.
8. Conclusion
The D1 dopamine receptors supersensitivity in striato-nigral neurons are closely related
with LID with a central role of adenylyl cyclase, co-expression of D3 receptors with D1 re‐
ceptors and the modifications of their interaction during experimental Parkinson and LID
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suggested a promissory therapeutical alternative in the management of motor disabilities re‐
lated with L-DOPA administration.
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